NEW YORK, April 7, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding
MannKind Corporation (NASDAQ: MNKD), Mylan Inc. (NASDAQ: MYL),
WellPoint Inc. (NYSE: WLP), Valeant Pharmaceuticals International
Inc. (NYSE: VRX), and Forest Laboratories Inc. (NYSE: FRX). Private
wealth members receive these notes ahead of publication. To reserve
complementary membership, limited openings are available at:
http://www.AnalystsReview.com/register
--
MannKind Corporation Analyst Notes
On April 1, 2014, MannKind
Corporation (MannKind) announced that the U.S. Food and Drug
Administration's (FDA) Endocrinologic and Metabolic Drugs Advisory
Committee has voted 13 to 1 to recommend that AFREZZA® (insulin
human [rDNA origin]) Inhalation Powder be granted marketing
approval by the FDA to improve glycemic control in adults with type
I diabetes. The same committee voted unanimously recommending that
AFREZZA be granted marketing approval by the FDA to improve
glycemic control in adults with type II diabetes. The Company
informed that if AFREZZA is approved, then it would be the first
ultra rapid-acting mealtime insulin therapy available in the U.S.
On April 2, 2014, the Company's stock
skyrocketed 73.88% to end the trading session at $6.99 following the news of recommendation of
AFREZZA. The full analyst notes on MannKind Corporation are
available to download free of charge at:
http://www.AnalystsReview.com/04072014/MNKD/report.pdf
--
Mylan Inc. Analyst Notes
On March 31, 2014, Mylan Inc.
(Mylan) issued a press release informing that the U.S. Supreme
Court has granted certiorari in the Company's patent litigation
against Teva pertaining to Mylan's Abbreviated New Drug Application
(ANDA) for glatiramer acetate (Copaxone). According to the press
release, in July 2013, the Court of
Appeals for the Federal Circuit ruled a decision that Teva's U.S.
Patent No. 5,800,808 (the '808 patent), along with other patents,
was invalid as indefinite. As stated, the Supreme Court is also
considering the issue of the standard of review that appellate
courts should apply when considering appeals relating to the
construction of a patent claim. The Supreme Court has also
agreed to consider a query of Teva that whether a legal review
of district court's factual finding in support of its construction
of a patent claim should be carried out, as the Federal Circuit
looks for clear factual errors. The full analyst notes on Mylan
Inc. are available to download free of charge at:
http://www.AnalystsReview.com/04072014/MYL/report.pdf
--
WellPoint Inc. Analyst Notes
On April 1, 2014, WellPoint Inc.
(WellPoint) announced that it has been awarded with the Corporate
Hispanic Health Leadership Award from the National Hispanic Medical
Association (NHMA) recognizing its efforts in educating the
Hispanic community on the Affordable Care Act. According to the
Company, NHMA has acknowledged the Company's efforts in helping to
enroll uninsured Hispanics in their communities. Dr. Antonio Linares, Regional Vice President and
Medical Director at WellPoint, said, "It is WellPoint's goal to
make sure that Hispanic American families in the communities we
serve can control their own health care journey by taking advantage
of their many new insurance options, including plans available
through the new exchanges." The full analyst notes on WellPoint
Inc. are available to download free of charge at:
http://www.AnalystsReview.com/04072014/WLP/report.pdf
--
Valeant Pharmaceuticals International Inc. Analyst
Notes
On April 2, 2014, shares of
Valeant Pharmaceuticals International Inc. (Valeant) moved up 0.33%
to end the trading session at $133.69, extending gains for the fourth
consecutive session. Valeant's stock opened the trading session at
$134.34 and fluctuated in the range
of $131.82 and $135.83. The stock has a 52-week high of
$153.10 and a 52-week low of
$69.87. Over the past three months,
the stock has gained 14.27%, outperforming the S&P 500 Index
which gained 3.22% over the same period. The full analyst notes on
Valeant Pharmaceuticals International Inc. are available to
download free of charge at:
http://www.AnalystsReview.com/04072014/VRX/report.pdf
--
Forest Laboratories Inc. Analyst Notes
On April 1, 2014, Forest
Laboratories Inc. (Forest Laboratories) announced that the Company
plans to release its Q4 FY 2014 results on April 29, 2014, before the opening of the U.S.
stock market. Following the earnings release, the Company will also
hold a conference call at 10:00 a.m.
EDT to discuss the financial results and relevant company
and industry issues. According to Zacks Investment Research data,
the consensus EPS forecast for Q4 FY 2014 is $0.44. The full analyst notes on Forest
Laboratories Inc. are available to download free of charge at:
http://www.AnalystsReview.com/04072014/FRX/report.pdf
--
About Analysts Review
We provide our members with a simple and reliable way to leverage
our economy of scale. Most investors do not have time to track all
publicly traded companies, much less perform an in-depth review and
analysis of the complexities contained in each situation. That's
where Analysts Review comes in. We provide a single unified
platform for investors' to hear about what matters. Situation
alerts, moving events, and upcoming opportunities.
--
=============
EDITOR NOTES:
- This is not company news. We are an independent source and our
views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a
best efforts basis and reviewed by Ananya
Ghosh, a CFA charterholder. However, we are only human and
are prone to make mistakes. If you notice any errors or omissions,
please notify us below.
- This information is submitted as a net-positive to companies
mentioned, to increase awareness for mentioned companies to our
subscriber base and the investing public.
- If you wish to have your company covered in more detail by our
team, or wish to learn more about our services, please contact us
at pubco [at] AnalystsReview.com.
- For any urgent concerns or inquiries, please contact us
at compliance [at] AnalystsReview.com.
- Are you a public company? Would you like to see similar
coverage on your company? Send us a full investors' package to
research [at] AnalystsReview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort
basis. This document, article or report is prepared and authored by
Analysts Review. An outsourced research services provider
represented by Ananya Ghosh, CFA,
has only reviewed the information provided by Analysts Review in
this article or report according to the Procedures outlined by
Analysts Review. Analysts Review is not entitled to veto or
interfere in the application of such procedures by the outsourced
provider to the articles, documents or reports, as the case may
be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to
the accuracy or completeness or fitness for a purpose (investment
or otherwise), of the information provided in this document. This
information is not to be construed as personal financial advice.
Readers are encouraged to consult their personal financial advisor
before making any decisions to buy, sell or hold any securities
mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be
occasioned at the time of printing of this document or any error,
mistake or shortcoming. No liability is accepted by Analysts Review
whatsoever for any direct, indirect or consequential loss arising
from the use of this document. Analysts Review expressly disclaims
any fiduciary responsibility or liability for any consequences,
financial or otherwise arising from any reliance placed on the
information in this document. Analysts Review does not (1)
guarantee the accuracy, timeliness, completeness or correct
sequencing of the information, or (2) warrant any results from use
of the information. The included information is subject to change
without notice.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
SOURCE Analysts Review